Locations
Conditions
Treatments
Institutions
Resources
For researchers
About us
Clinical trials
Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)
Apply
Enasidenib & Cedazuridine-Decitabine
Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)
Basic information
Step 1/5
Provide your basic information
Age
ZIP code
Back
Next step